133 related articles for article (PubMed ID: 12388660)
1. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs.
Schermuly RT; Schulz A; Ghofrani HA; Meidow A; Rose F; Roehl A; Weissmann N; Hildebrand M; Kurz J; Grimminger F; Walmrath D; Seeger W
J Pharmacol Exp Ther; 2002 Nov; 303(2):741-5. PubMed ID: 12388660
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development.
Schermuly RT; Schulz A; Ghofrani HA; Breitenbach CS; Weissmann N; Hildebrand M; Kurz J; Grimminger F; Seeger W
J Aerosol Med; 2006; 19(3):353-63. PubMed ID: 17034310
[TBL] [Abstract][Full Text] [Related]
3. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.
Schermuly RT; Krupnik E; Tenor H; Schudt C; Weissmann N; Rose F; Grimminger F; Seeger W; Walmrath D; Ghofrani HA
Am J Respir Crit Care Med; 2001 Nov; 164(9):1694-700. PubMed ID: 11719312
[TBL] [Abstract][Full Text] [Related]
4. Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs.
Schermuly RT; Pullamsetti SS; Breitenbach SC; Weissmann N; Ghofrani HA; Grimminger F; Nilius SM; Schrör K; Kirchrath JM; Seeger W; Rose F
Respir Res; 2007 Jan; 8(1):4. PubMed ID: 17257398
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients.
Hildebrand M
Eur J Clin Pharmacol; 1997; 53(1):51-6. PubMed ID: 9349930
[TBL] [Abstract][Full Text] [Related]
6. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbruck B; Grimminger F; Seeger W
Am J Respir Crit Care Med; 1999 Aug; 160(2):600-7. PubMed ID: 10430735
[TBL] [Abstract][Full Text] [Related]
7. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
8. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.
Schermuly RT; Inholte C; Ghofrani HA; Gall H; Weissmann N; Weidenbach A; Seeger W; Grimminger F
Respir Res; 2005 Jul; 6(1):76. PubMed ID: 16033645
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension.
Olschewski H; Rohde B; Behr J; Ewert R; Gessler T; Ghofrani HA; Schmehl T
Chest; 2003 Oct; 124(4):1294-304. PubMed ID: 14555558
[TBL] [Abstract][Full Text] [Related]
10. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease.
Yin N; Kaestle S; Yin J; Hentschel T; Pries AR; Kuppe H; Kuebler WM
Crit Care Med; 2009 Mar; 37(3):980-6. PubMed ID: 19237907
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.
Opitz CF; Wensel R; Bettmann M; Schaffarczyk R; Linscheid M; Hetzer R; Ewert R
Eur Heart J; 2003 Feb; 24(4):356-65. PubMed ID: 12581683
[TBL] [Abstract][Full Text] [Related]
12. Effects of inhaled aerosolized iloprost and inhaled NO on pulmonary circulation and edema formation in ovine lung injury.
Hucklenbruch C; Hinder F; Berger C; Ertmer C; Lange M; Westphal M; Van Aken H; Ellger B; Dirk Stubbe H
Shock; 2008 Jul; 30(1):75-80. PubMed ID: 18562927
[TBL] [Abstract][Full Text] [Related]
13. Inhalative pre-treatment of donor lungs using the aerosolized prostacyclin analog iloprost ameliorates reperfusion injury.
Wittwer T; Franke UF; Ochs M; Sandhaus T; Schuette A; Richter S; Dreyer N; Knudsen L; Müller T; Schubert H; Richter J; Wahlers T
J Heart Lung Transplant; 2005 Oct; 24(10):1673-9. PubMed ID: 16210146
[TBL] [Abstract][Full Text] [Related]
14. [Inhalation of a prostacyclin analog (iloprost) in primary and secondary pulmonary hypertension].
Andreassen AK; Madsen S; Kjekshus J; Simonsen S
Tidsskr Nor Laegeforen; 2001 Apr; 121(10):1220-3. PubMed ID: 11402748
[TBL] [Abstract][Full Text] [Related]
15. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension.
Schenk P; Petkov V; Madl C; Kramer L; Kneussl M; Ziesche R; Lang I
Chest; 2001 Jan; 119(1):296-300. PubMed ID: 11157622
[TBL] [Abstract][Full Text] [Related]
16. Inhaled iloprost in pulmonary arterial hypertension.
Baker SE; Hockman RH
Ann Pharmacother; 2005; 39(7-8):1265-74. PubMed ID: 15976392
[TBL] [Abstract][Full Text] [Related]
17. Inhaled prostanoids in the therapy of pulmonary hypertension.
Gessler T; Seeger W; Schmehl T
J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):1-12. PubMed ID: 18518827
[TBL] [Abstract][Full Text] [Related]
18. Inhaled iloprost for therapy in pulmonary arterial hypertension.
Ewert R; Gläser S; Bollmann T; Schäper C
Expert Rev Respir Med; 2011 Apr; 5(2):145-52. PubMed ID: 21510725
[TBL] [Abstract][Full Text] [Related]
19. Comparison of acute hemodynamic effects of aerosolized iloprost and inhaled nitric oxide in adult congenital heart disease with severe pulmonary arterial hypertension.
Caojin Z; Yigao H; Tao H; Wenhui H; Chunli X; Xinsheng H
Intern Med; 2012; 51(20):2857-62. PubMed ID: 23064558
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis.
Hildebrand M; Krause W; Fabian H; Koziol T; Neumayer HH
Int J Clin Pharmacol Res; 1990; 10(5):285-92. PubMed ID: 1706685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
